Denosumab  (Synonyms: 地舒单抗)

Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies^{[1][2][3][4][5][6][7]}.

Denosumab (0.25-20 μM，7 天) 在生理浓度下可增强人类颌骨间充质干细胞的成骨分化能力^[4]。
Denosumab (0.1 μM-5 μM) 可缓解 ROS 诱导的软骨细胞凋亡，促进 Bcl-2，抑制促凋亡基因Bax 和 caspase-3^[5]。
Denosumab (5 μM，5-60 min) 通过抑制 NF-κB 信号通路抑制 RANKL 诱导的破骨细胞生成^[5]。
Denosumab (0.001-0.1 μg/mL，24-72 h) 可显著促进人 β 细胞增殖^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Denosumab (10 mg/kg，皮下注射，每周两次，连续 4 周) 可改善骨关节炎 (OA) 小鼠模型中与疼痛相关的行为和骨关节炎的发展^[5]。
Denosumab (1 mg/kg，皮下注射，单次) 可增强雄性优血型 NOD/SCID 小鼠肾囊下移植的人胰岛中 β 细胞的增殖能力^[6]。
Denosumab (5 mg/kg，皮下注射，单次) 可增加人源化 RANKL 小鼠的睾丸重量、抑制素 B 和精子数量^[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

144716.86

C₆₄₀₄H₉₉₀₈N₁₇₂₄O₂₀₀₄S₅₀

615258-40-7

液体

Colorless to light yellow

地舒单抗； 地诺单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized RANKL/TNFSF11 Protein, Human (HY-P7424) can bind Denosumab. The EC₅₀ for this effect is 18.6 ng/mL.

• [1]. 1. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.  [Content Brief]

  [2]. 2. Kendler DL, et al. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74.  [Content Brief]

  [3]. 3. Dell'Aquila E, et al. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020 Nov;20(11):1261-1274.  [Content Brief]

  [4]. 4. Mosch A, et al. Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. Arch Oral Biol. 2019 May;101:23-29.  [Content Brief]

  [5]. 5. Shangguan L, et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen Ther. 2024 Mar 26;27:181-190.  [Content Brief]

  [6]. 6. Kondegowda NG, et al. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metab. 2015 Jul 7;22(1):77-85.  [Content Brief]

  [7]. 7. Andreassen CH, et al. Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity. Cell Rep Med. 2024 Oct 15;5(10):101783.  [Content Brief]